Eli Lilly Shares Surge 10% as Weight-Loss Drug Sales Drive Profits to Nearly Double
Eli Lilly's stock soared after reporting a 95% jump in annual net income, fueled by blockbuster demand for its diabetes and obesity treatments Zepbound and Mounjaro. The pharmaceutical giant also issued robust revenue guidance for 2026.